Sells Deep TMS systems for depression, obsessive-compulsive disorder and smoking cessation to psychiatrists and other treatment facilities.
20-F for FY2025, filed Apr 20, 2026BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The Company is boldly…View ↗
We have also received CE Mark for a variety of psychiatric and neurological indications. We are focused on increasing global awareness of…View ↗
Our first commercial H1 Coil Deep TMS product received clearance from the FDA in 2013 for the treatment of MDD in adult patients who have…View ↗
Customers buy systems for a fixed price, with the sale counted when the system ships, or lease them for fixed fees paid over the lease term. Extended-warranty fees are spread across the service period.
20-F for FY2025, filed Apr 20, 2026Revenue from sale of systems is recognized at the point in time when control of the system is transferred to the customer, generally upon…View ↗
Revenue from rendering of extended warranty services are recognized ratably over the contract period as the services have a consistent…View ↗
A lease in which substantially all the risks and rewards incidental to ownership of the leased asset have not been transferred to the…View ↗
$52.2M
20-F for FY2025, filed Apr 20, 2026
$52.2M ↗
In the United States, psychiatrists’ offices and other facilities buy or lease Deep TMS systems through BrainsWay’s own sales channel.
20-F for FY2025, filed Apr 20, 2026Our first commercial H1 Coil Deep TMS product received clearance from the FDA in 2013 for the treatment of MDD in adult patients who have…View ↗
The United States is our primary and most strategic market, representing approximately 85%, 81% and 75% of our revenues for the years ended…View ↗
In the United States, we sell or lease Deep TMS systems by one of the following two methods: (i) a fixed-fee lease model in which the Deep…View ↗
Growing. Revenue grew 76% in 4 years, from $29.7M in FY2021 to $52.2M in FY2025, about 15% a year.
Broader MDD patient group
The MDD offering has expanded from adult patients to include adolescents, for whom the treatment is used as an adjunct therapy.
20-F for FY2022, filed Mar 27, 2023 20-F for FY2025, filed Apr 20, 2026Our first commercial H1 Coil Deep TMS product received clearance from the FDA in 2013 for the treatment of MDD in adult patients who have…View ↗
In November 2025, the FDA cleared an expansion of our existing MDD clearance allowing for the treatment of adolescent patients (ages 15-21)…View ↗
Loading...